<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15585605</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>05</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0953-8178</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2005</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunology</Title>
          <ISOAbbreviation>Int Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Toll-like receptors in innate immunity.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>14</EndPage>
          <MedlinePgn>1-14</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Functional characterization of Toll-like receptors (TLRs) has established that innate immunity is a skillful system that detects invasion of microbial pathogens. Recognition of microbial components by TLRs initiates signal transduction pathways, which triggers expression of genes. These gene products control innate immune responses and further instruct development of antigen-specific acquired immunity. TLR signaling pathways are finely regulated by TIR domain-containing adaptors, such as MyD88, TIRAP/Mal, TRIF and TRAM. Differential utilization of these TIR domain-containing adaptors provides specificity of individual TLR-mediated signaling pathways. Several mechanisms have been elucidated that negatively control TLR signaling pathways, and thereby prevent overactivation of innate immunity leading to fatal immune disorders. The involvement of TLR-mediated pathways in autoimmune and inflammatory diseases has been proposed. Thus, TLR-mediated activation of innate immunity controls not only host defense against pathogens but also immune disorders.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takeda</LastName>
            <ForeName>Kiyoshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akira</LastName>
            <ForeName>Shizuo</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Int Immunol</MedlineTA>
        <NlmUniqueID>8916182</NlmUniqueID>
        <ISSNLinking>0953-8178</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>136</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15585605</ArticleId>
        <ArticleId IdType="doi">10.1093/intimm/dxh186</ArticleId>
        <ArticleId IdType="pii">17/1/1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
